InvestorsHub Logo
icon url

falconer66a

05/21/24 4:51 PM

#459514 RE: georgejjl #459512

Rewarding Margins on Both Sides

Pantheon and Syntagon combined give Anavex the production process control and capacity to produce Blarcamesine for commercialization and worldwide distribution and sales.

Well, when chemical engineers at either of these firms learn of how much their companies can make as contract manufacturers of either Anavex 3-71 or blarcamesine, when they see how these molecules can be synthesized in quantity and quality, at minimal cost, they will encourage the management of their companies to start talking seriously with Missling and company.

The Anavex molecules are very different from those in the monoclonal antibodies (MABs) of other CNS treatment drugs. MABs are expensive and difficult to synthesize. Not so with the relatively simple structures of the Anavex molecules. No comparison. Doses of the Anavex drugs will be made for pennies each. But sold for dollars each. Big margins for the companies and their shareholders; both the contract manufacturers and Anavex.